Skip to main content
. 2020 Dec 3;9(1):255–264. doi: 10.1002/iid3.388

Figure 3.

Figure 3

MicroR‐2355‐3p is a potential target miRNA (miR) of SOX2‐OT. (A) MicroRNA binding with SOX2‐OT and the 3′‐UTR of NLRP3 in miR‐2355‐3p was analyzed using starBase 3.0 and target 7.2. (B) Expression of miR‐2355‐3p measured by qRT‐PCR in sham, HF, VA‐HF‐control, and VA‐HF groups. (C) Expression miR‐2355‐3p measured by qRT‐PCR in si‐NC and si‐SOX2‐OT at 6 weeks after injection in rats with VA‐HF. (D) Binding between miR‐2355‐3p and SOX2‐OT. (E) Binding between miR‐2355‐3p and 3′‐UTR NLRP3 analyzed by dual‐luciferase reporter gene assays. GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; HF, heart failure; IL‐1β, interleukin‐1β; Mut, mutant; NLRP3, nucleotide‐binding oligomerization domain‐like receptor family pyrin domain containing 3; qRT‐PCR, quantitative reverse transcriptase‐polymerase chain reaction; ROS, reactive oxygen species; si‐NC, small interfering negative control; SOX2‐OT, SOX2‐overlapping transcripts; TGF‐β1, transforming growth factor‐β1; UTR, untranslated region; VA, ventricular arrhythmia; WT, wild‐type. *p < .05